Delhi High Court Restrains NPPA From Recovering ₹151 Crore From AstraZeneca in Symbicort Pricing Case
The AstraZeneca ₹151 crore case shows how classification disputes can create pricing liabilities for drugmakers in India; recovery is paused until 11 January.